Vi­en­na-based vac­cine de­vel­op­er Themis signs pact with Mer­ck for 'block­buster in­di­ca­tion'

Months af­ter se­cur­ing up to $21 mil­lion in fund­ing from the Coali­tion for Epi­dem­ic Pre­pared­ness In­no­va­tions (CEPI) for its Chikun­gun­ya vac­cine — which is be­ing prepped …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER